# Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne

Source: https://onco.cc/trials/nct04842617/  
OnCo record `nct04842617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dalpiciclib in male breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative is a phase 3 interventional study registered as NCT04842617 by Jiangsu HengRui Medicine Co., Ltd., with 5274 participants enrolled, started 2021-04-30 and due to reach its primary completion in 2026-10-31. Interventions recorded: SHR6390, placebo. Conditions listed: Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04842617
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind Phase III Study：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 5274

## Sources

- ClinicalTrials.gov NCT04842617: https://clinicaltrials.gov/study/NCT04842617

## Connected records

- cancers: [Male breast cancer](https://onco.cc/cancers/male-breast-cancer/)
- drugs: [Dalpiciclib](https://onco.cc/drugs/dalpiciclib/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct04842617.json